These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
660 related articles for article (PubMed ID: 30582156)
1. Long-term cannabidiol treatment in patients with Dravet syndrome: An open-label extension trial. Devinsky O; Nabbout R; Miller I; Laux L; Zolnowska M; Wright S; Roberts C Epilepsia; 2019 Feb; 60(2):294-302. PubMed ID: 30582156 [TBL] [Abstract][Full Text] [Related]
2. Add-on cannabidiol in patients with Dravet syndrome: Results of a long-term open-label extension trial. Scheffer IE; Halford JJ; Miller I; Nabbout R; Sanchez-Carpintero R; Shiloh-Malawsky Y; Wong M; Zolnowska M; Checketts D; Dunayevich E; Devinsky O Epilepsia; 2021 Oct; 62(10):2505-2517. PubMed ID: 34406656 [TBL] [Abstract][Full Text] [Related]
3. Don't Fear the Reefer-Evidence Mounts for Plant-Based Cannabidiol as Treatment for Epilepsy. Perry MS Epilepsy Curr; 2019; 19(2):93-95. PubMed ID: 30955420 [TBL] [Abstract][Full Text] [Related]
4. Cannabidiol in patients with Lennox-Gastaut syndrome: Interim analysis of an open-label extension study. Thiele E; Marsh E; Mazurkiewicz-Beldzinska M; Halford JJ; Gunning B; Devinsky O; Checketts D; Roberts C Epilepsia; 2019 Mar; 60(3):419-428. PubMed ID: 30740695 [TBL] [Abstract][Full Text] [Related]
5. Long-term safety and efficacy of add-on cannabidiol in patients with Lennox-Gastaut syndrome: Results of a long-term open-label extension trial. Patel AD; Mazurkiewicz-Bełdzińska M; Chin RF; Gil-Nagel A; Gunning B; Halford JJ; Mitchell W; Scott Perry M; Thiele EA; Weinstock A; Dunayevich E; Checketts D; Devinsky O Epilepsia; 2021 Sep; 62(9):2228-2239. PubMed ID: 34287833 [TBL] [Abstract][Full Text] [Related]
6. Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results. Laux LC; Bebin EM; Checketts D; Chez M; Flamini R; Marsh ED; Miller I; Nichol K; Park Y; Segal E; Seltzer L; Szaflarski JP; Thiele EA; Weinstock A; Epilepsy Res; 2019 Aug; 154():13-20. PubMed ID: 31022635 [TBL] [Abstract][Full Text] [Related]
7. Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome: A Randomized Clinical Trial. Miller I; Scheffer IE; Gunning B; Sanchez-Carpintero R; Gil-Nagel A; Perry MS; Saneto RP; Checketts D; Dunayevich E; Knappertz V; JAMA Neurol; 2020 May; 77(5):613-621. PubMed ID: 32119035 [TBL] [Abstract][Full Text] [Related]
8. Time to onset of cannabidiol treatment effects in Dravet syndrome: Analysis from two randomized controlled trials. Madan Cohen J; Checketts D; Dunayevich E; Gunning B; Hyslop A; Madhavan D; Villanueva V; Zolnowska M; Zuberi SM Epilepsia; 2021 Sep; 62(9):2218-2227. PubMed ID: 34265088 [TBL] [Abstract][Full Text] [Related]
9. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. Devinsky O; Cross JH; Laux L; Marsh E; Miller I; Nabbout R; Scheffer IE; Thiele EA; Wright S; N Engl J Med; 2017 May; 376(21):2011-2020. PubMed ID: 28538134 [TBL] [Abstract][Full Text] [Related]
10. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Thiele EA; Marsh ED; French JA; Mazurkiewicz-Beldzinska M; Benbadis SR; Joshi C; Lyons PD; Taylor A; Roberts C; Sommerville K; Lancet; 2018 Mar; 391(10125):1085-1096. PubMed ID: 29395273 [TBL] [Abstract][Full Text] [Related]
12. Long-Term Safety, Tolerability, and Efficacy of Cannabidiol in Children with Refractory Epilepsy: Results from an Expanded Access Program in the US. Sands TT; Rahdari S; Oldham MS; Caminha Nunes E; Tilton N; Cilio MR CNS Drugs; 2019 Jan; 33(1):47-60. PubMed ID: 30460546 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Cannabidiol in Epilepsy: A Systematic Review and Meta-Analysis. Lattanzi S; Brigo F; Trinka E; Zaccara G; Cagnetti C; Del Giovane C; Silvestrini M Drugs; 2018 Nov; 78(17):1791-1804. PubMed ID: 30390221 [TBL] [Abstract][Full Text] [Related]
14. Long-term safety and treatment effects of cannabidiol in children and adults with treatment-resistant epilepsies: Expanded access program results. Szaflarski JP; Bebin EM; Comi AM; Patel AD; Joshi C; Checketts D; Beal JC; Laux LC; De Boer LM; Wong MH; Lopez M; Devinsky O; Lyons PD; Zentil PP; Wechsler R; Epilepsia; 2018 Aug; 59(8):1540-1548. PubMed ID: 29998598 [TBL] [Abstract][Full Text] [Related]
15. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Devinsky O; Marsh E; Friedman D; Thiele E; Laux L; Sullivan J; Miller I; Flamini R; Wilfong A; Filloux F; Wong M; Tilton N; Bruno P; Bluvstein J; Hedlund J; Kamens R; Maclean J; Nangia S; Singhal NS; Wilson CA; Patel A; Cilio MR Lancet Neurol; 2016 Mar; 15(3):270-8. PubMed ID: 26724101 [TBL] [Abstract][Full Text] [Related]
17. Caregiver-reported outcomes with real-world use of cannabidiol in Lennox-Gastaut syndrome and Dravet syndrome from the BECOME survey. Berg AT; Dixon-Salazar T; Meskis MA; Danese SR; Le NMD; Perry MS Epilepsy Res; 2024 Feb; 200():107280. PubMed ID: 38183688 [TBL] [Abstract][Full Text] [Related]
18. Adjunctive Cannabidiol in Patients with Dravet Syndrome: A Systematic Review and Meta-Analysis of Efficacy and Safety. Lattanzi S; Brigo F; Trinka E; Zaccara G; Striano P; Del Giovane C; Silvestrini M CNS Drugs; 2020 Mar; 34(3):229-241. PubMed ID: 32040850 [TBL] [Abstract][Full Text] [Related]